0001558370-23-010189.txt : 20230518 0001558370-23-010189.hdr.sgml : 20230518 20230518160525 ACCESSION NUMBER: 0001558370-23-010189 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230512 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20230518 DATE AS OF CHANGE: 20230518 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NeuBase Therapeutics, Inc. CENTRAL INDEX KEY: 0001173281 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 465622433 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35963 FILM NUMBER: 23936052 BUSINESS ADDRESS: STREET 1: 350 TECHNOLOGY DRIVE CITY: PITTSBURGH STATE: PA ZIP: 15219 BUSINESS PHONE: 412-763-3350 MAIL ADDRESS: STREET 1: 350 TECHNOLOGY DRIVE CITY: PITTSBURGH STATE: PA ZIP: 15219 FORMER COMPANY: FORMER CONFORMED NAME: Ohr Pharmaceutical Inc DATE OF NAME CHANGE: 20090819 FORMER COMPANY: FORMER CONFORMED NAME: BBM HOLDINGS, INC. DATE OF NAME CHANGE: 20070402 FORMER COMPANY: FORMER CONFORMED NAME: PRIME RESOURCE INC DATE OF NAME CHANGE: 20020513 8-K 1 nbse-20230512x8k.htm 8-K
0001173281false00011732812023-05-122023-05-12

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 12, 2023

NeuBase Therapeutics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

​

​

​

Delaware

    

001-35963

    

46-5622433

(State or Other Jurisdiction
of Incorporation)

​

(Commission
File Number)

​

(I.R.S. Employer
Identification No.)

​

​

350 Technology Drive, Pittsburgh, PA

15219

(Address of Principal Executive Offices)

(Zip Code)

​

​

 

(412) 763-3350

 

(Registrant’s Telephone Number, Including Area Code)

​

​

 

N/A

 

(Former Name or Former Address, if Changed Since
Last Report)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

​

​

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

​

​

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

​

​

​

☐

​

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

NBSE

The Nasdaq Stock Market LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

​

​

​

​

​

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On May 12, 2023, Eric J. Ende, M.D. notified NeuBase Therapeutics, Inc. (the “Company”) of his resignation from the Board of Directors (the “Board”) of the Company, effective May 12, 2023. Dr. Ende served as a member of the Nominating and Corporate Governance Committee of the Board and the Compensation Committee of the Board. Dr. Ende’s resignation is not a result of any disagreement with the Company on any matter relating to the Company’s policies or procedures.

​

​

​

​

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

NEUBASE THERAPEUTICS, INC.
(Registrant)

 

 

Date: May 18, 2023

By:

/s/ Todd P. Branning

 

 

Todd P. Branning

 

 

Chief Financial Officer

​

​

​

 EX-101.SCH 2 nbse-20230512.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 nbse-20230512_lab.xml EX-101.LAB EX-101.PRE 4 nbse-20230512_pre.xml EX-101.PRE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
May 12, 2023
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date May 12, 2023
Entity File Number 001-35963
Entity Registrant Name NeuBase Therapeutics, Inc.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 46-5622433
Entity Address State Or Province PA
Entity Address, Address Line One 350 Technology Drive
Entity Address, City or Town Pittsburgh
Entity Address, Postal Zip Code 15219
City Area Code 412
Local Phone Number 763-3350
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol NBSE
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001173281
Amendment Flag false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
XML 6 nbse-20230512x8k_htm.xml IDEA: XBRL DOCUMENT 0001173281 2023-05-12 2023-05-12 0001173281 false 8-K 2023-05-12 NeuBase Therapeutics, Inc. DE 001-35963 46-5622433 350 Technology Drive Pittsburgh PA 15219 412 763-3350 false false false false Common Stock, par value $0.0001 per share NBSE NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 22 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://neubasetherapeutics.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports nbse-20230512x8k.htm nbse-20230512.xsd nbse-20230512_lab.xml nbse-20230512_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nbse-20230512x8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "nbse-20230512x8k.htm" ] }, "labelLink": { "local": [ "nbse-20230512_lab.xml" ] }, "presentationLink": { "local": [ "nbse-20230512_pre.xml" ] }, "schema": { "local": [ "nbse-20230512.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "nbse", "nsuri": "http://neubasetherapeutics.com/20230512", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "nbse-20230512x8k.htm", "contextRef": "Duration_5_12_2023_To_5_12_2023_0aixy33mY0yfv7y4DBTq-w", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://neubasetherapeutics.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "nbse-20230512x8k.htm", "contextRef": "Duration_5_12_2023_To_5_12_2023_0aixy33mY0yfv7y4DBTq-w", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://neubasetherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://neubasetherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://neubasetherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://neubasetherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://neubasetherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://neubasetherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://neubasetherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://neubasetherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://neubasetherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://neubasetherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://neubasetherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://neubasetherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://neubasetherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://neubasetherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://neubasetherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://neubasetherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://neubasetherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://neubasetherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://neubasetherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://neubasetherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://neubasetherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://neubasetherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 13 0001558370-23-010189-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-23-010189-xbrl.zip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